Improving liver transplant outcomes using a new protective agent for donor organs
Preservation of DCD Allograft Integrity for Liver Transplantation
This study is looking at a special treatment that could help keep donated livers healthy and working better during transplants, which might lead to fewer problems for patients getting liver transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10747848 on NIH RePORTER |
What this research studies
This research focuses on enhancing the preservation of liver organs donated after cardiac death (DCD) to improve transplant outcomes. It investigates the use of a therapeutic agent called recombinant human MG53, which has shown promise in protecting liver cells from damage during the transplantation process. By utilizing a specialized technique called normothermic ex-vivo liver perfusion, the study aims to assess how MG53 can maintain the integrity of liver grafts, potentially reducing complications like early allograft dysfunction. Patients receiving liver transplants may benefit from improved organ function and reduced risk of transplant failure.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with end-stage liver disease who are awaiting liver transplantation.
Not a fit: Patients who are not candidates for liver transplantation or those receiving organs from living donors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better preservation of liver donor organs, resulting in improved transplant success rates and patient outcomes.
How similar studies have performed: Previous research has indicated that similar approaches to organ preservation have shown promise, making this a potentially impactful area of investigation.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Black, Sylvester M — Ohio State University
- Study coordinator: Black, Sylvester M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.